An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies

Cancer Biomarkers

Volumn 12, Issue 1, 2012, Pages 37-47

  Shao, Ning ^a   Jiang, Wen Yu ^b   Qiao, Di ^a   Zhang, Shi Ge ^a   Wu, Ye ^a   Zhang, Xiang Xiang ^a   Hua, Li Xin ^b   Ding, Yi ^a   Feng, Ning Han ^b  

^a Jiangsu Province Geriatric Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; Polymorphism; XRCC4

Indexed keywords

XRCC4 PROTEIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; META ANALYSIS; MOUTH CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PUBLICATION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84872830950     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-120292     Document Type: Article

References (46)

1. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011; 129(7): 1730-1740.
2. Wang B, Wang D, Zhang D, Li A, Liu D, Liu H, Jin H. Pro variant of TP53Arg72Pro contributes to esophageal squamous cell carcinoma risk: evidence from a meta-analysis. Eur J Cancer Prev 2010; 19(4): 299-307.
3. Shao N, Xu B, Mi YY, Hua LX. IL-10 polymorphisms and prostate cancer risk: ameta-analysis. Prostate Cancer Prostatic Dis 2011; 14(2): 129-135.
4. Mari PO, Florea BI, Persengiev SP, Verkaik NS, Bruggenwirth HT, Modesti M, Giglia-Mari G, Bezstarosti K, Demmers JA, Luider TM, Houtsmuller AB, van Gent DC. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci USA 2006; 103(49): 18597-18602. (Pubitemid 44913456)
5. van Heemst D, Brugmans L, Verkaik NS, van Gent DC. Endjoining of blunt DNA double-strand breaks in mammalian fibroblasts is precise and requires DNA-PKand XRCC4. DNA Repair (Amst) 2004; 3(1): 43-50. (Pubitemid 38021994)
6. Berwick M, Vineis P. RESPONSE re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92(18): 1537.
7. Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer 2011.
8. MittalRD,Gangwar R,MandalRK, Srivastava P,AhirwarDK. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. Mol Biol Rep 2011.
9. Bau DT, Yang MD, Tsou YA, Lin SS, Wu CN, Hsieh HH, Wang RF, Tsai CW, Chang WS, Hsieh HM, Sun SS, Tsai RY. Colorectal cancer and genetic polymorphism of DNA doublestrand break repair gene XRCC4 in Taiwan. Anticancer Res 2010; 30(7): 2727-2730.
10. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Kim HJ, Chung IJ. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010; 101(5): 1247-1254.
11. Gomes BC, Silva SN, Azevedo AP, Manita I, Gil OM, Ferreira TC, Limbert E, Rueff J, Gaspar JF. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep 2010; 24(4): 1079-1085.
12. Broberg K, Bjork J, Paulsson K, HoglundM, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005; 26(7): 1263-1271. (Pubitemid 41417904)
13. Chiu CF, Wang HC, Wang CH, Wang CL, Lin CC, Shen CY, Chiang SY, Bau DT. A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients. Anticancer Res 2008; 28(1A): 267-270.
14. Chiu CF, Tsai MH, Tseng HC, Wang CL, Wang CH, Wu CN, Lin CC, Bau DT. A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients. Oral Oncol 2008; 44(9): 898-902.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188. (Pubitemid 17189972)
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22(4): 719-748.
17. Lewontin RC. On measures of gametic disequilibrium. Genetics 1988; 120(3): 849-852. (Pubitemid 18260517)
18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002; 296(5576): 2225-2229. (Pubitemid 34680308)
19. Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Rothman N, Linet MS, Inskip PD. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 2010; 12(1): 37-48.
20. Yu H, Zhao H, Wang LE, Han Y, Chen WV, Amos CI, Rafnar T, Sulem P, Stefansson K, LandiMT, Caporaso N, Albanes D, Thun M, McKay JD, Brennan P, Wang Y, Houlston RS, Spitz MR, Wei Q. An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. DNA Repair (Amst) 2011; 10(4): 398-407.
21. Hsu NY, Wang HC, Wang CH, Chang CL, Chiu CF, Lee HZ, Tsai CW, Bau DT. Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan. Cancer Biomark 2009; 5(4): 159-165.
22. Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YC. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer 2009; 115(13): 2939-2948.
23. Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M, Chanock S, Yeager M, Welch R, Dosemeci M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Castano-Vinyals G, Garcia-Closas M. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007; 28(8): 1788-1793. (Pubitemid 47289043)
24. Chang CH, Chang CL, Tsai CW, Wu HC, Chiu CF, Wang RF, Liu CS, Lin CC, Bau DT. Significant association of an XRCC4 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 2009; 29(5): 1777-1782.
25. Long XD, Ma Y, Huang YZ, Yi Y, Liang QX, Ma AM, Zeng LP, Fu GH. Genetic polymorphisms inDNArepair genesXPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China. Mol Carcinog 2010; 49(6): 611-618.
26. Chiu CF, Wang CH, Wang CL, Lin CC, Hsu NY, Weng JR, Bau DT. A novel single nucleotide polymorphism in XRCC4 gene is associated with gastric cancer susceptibility in Taiwan. Ann Surg Oncol 2008; 15(2): 514-518.
27. Shen M, Menashe I, Morton LM, Zhang Y, Armstrong B, Wang SS, Lan Q, Hartge P, Purdue MP, Cerhan JR, Grulich A, Cozen W, Yeager M, Holford TR, Vajdic CM, Davis S, Leaderer B, Kricker A, Severson RK, Zahm SH, Chatterjee N, Rothman N, Chanock SJ, Zheng T. Polymorphisms in DNArepair genes and risk of non-Hodgkin lymphoma in a pooled analysis of three studies. Br J Haematol 2010; 151(3): 239-244.
28. Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al-Sanea O, Uddin S, Al-Kuraya K. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest 2008; 31(10): 893-899.
29. Chang CH, Chiu CF, Wu HC, Tseng HC, Wang CH, Lin CC, Tsai CW, Liang SY, Wang CL, Bau DT. Significant association ofXRCC4 single nucleotide polymorphisms with prostate cancer susceptibility in Taiwanese males. Mol Med Report 2008; 1(4): 525-530.
30. Mandal RK, Singh V, Kapoor R, Mittal RD. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population? Biomarkers 2011; 16(3): 236-242.
31. Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol Biomarkers Prev 2009; 18(11): 3030-3035.
32. Hsieh YY, Chang CC, Bau DT, Yeh LS, Tsai FJ, Tsai CH. X-ray repair cross-complementing group 4 (XRCC4) promoter -1394(*)T-related genotype, but not XRCC4 codon 247/intron 3 or xeroderma pigmentosum group D codon 312, 751/promoter -114, polymorphisms are correlated with higher susceptibility to myoma. Fertil Steril 2008; 90(4 Suppl): 1417-1423.
33. Tseng HC, Tsai MH, Chiu CF, Wang CH, Chang NW, Huang CY, Tsai CW, Liang SY, Wang CL, Bau DT. Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res 2008; 28(3A): 1687-1691.
34. Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med 2008; 37(5): 271-277.
35. Fu YP, Yu JC, Cheng TC, LouMA, Hsu GC,Wu CY, Chen ST, Wu HS, Wu PE, Shen CY. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: amultigenic study on cancer susceptibility. Cancer Res 2003; 63(10): 2440-2446. (Pubitemid 36605181)
36. Lee KM, Choi JY, Kang C, Kang CP, Park SK, Cho H, Cho DY, YooKY, NohDY, Ahn SH, ParkCG,WeiQ, KangD.Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 2005; 11(12): 4620-4626. (Pubitemid 40825653)
37. Garcia-ClosasM, EganKM,Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006; 119(4): 376-388.
38. Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjose S, Foretova L, Maynadie M, Cocco PL, Boffetta P, Brennan P, Chanock SJ, Browne PV, Lawler M. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility tomyeloma. Hum Mol Genet 2007; 16(24): 3117-3127. (Pubitemid 350131330)
39. Margulis V, Lin J, Yang H,WangW,Wood CG,WuX.Genetic susceptibility to renal cell carcinoma: the role ofDNA doublestrand break repair pathway. Cancer Epidemiol Biomarkers Prev 2008; 17(9): 2366-2373.
40. Wu KH, Wang CH, Yang YL, Peng CT, Lin WD, Tsai FJ, Lin DT, Bau DT. Significant association of XRCC4 single nucleotide polymorphisms with childhood leukemia in Taiwan. Anticancer Res 2010; 30(2): 529-533.
41. Weterings E, van Gent DC. The mechanism of nonhomologous end-joining: a synopsis of synapsis. DNA Repair (Amst) 2004; 3(11): 1425-1435. (Pubitemid 39221740)
42. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003; 85(11): 1161-1173. (Pubitemid 38142369)
43. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006; 124(2): 301-313. (Pubitemid 43121979)
44. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279(4): 281-286.
45. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267(3): 374-378.
46. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337(8746): 867-872.